Yalvaç 1996.

Methods	Study design: parallel‐group RCT Country: Turkey Number randomized: Total: 48 Per group: apraclonidine/180° ALT = 16, apraclonidine/360° ALT = 16, placebo/180° ALT = 16 Exclusions after randomization: none reported Number analyzed: Total: 48 Per group: apraclonidine/180° ALT = 16, apraclonidine/360° ALT = 16, placebo/180° ALT = 16 Unit of analysis (participants vs eyes): participant (1 eye per person) Losses to follow‐up: none reported How was missing data handled?: N/A Reported power calculation: no Unusual study design?: none
Participants	Age (mean ± SD; years): apraclonidine/180° ALT = 63.3 ± 8.8, apraclonidine/360° ALT = 65.5 ± 7.4, placebo/180° ALT = 62.1 ± 8.3 Females: apraclonidine/180° ALT = 25%, apraclonidine/360° ALT = 38%, placebo/180° ALT = 31% Inclusion criteria: people with POAG, defined by optic disk cupping and visual field loss and a pretreatment IOP > 21 mmHg on maximally tolerated medical therapy Exclusion criteria: previous intraocular surgical procedures or laser treatment, secondary OAG (i.e. pigmentary, exfoliative, or uveitic), and aged < 40 years Equivalence of baseline characteristics: yes, "There were no significant differences among the three groups in terms of average age, gender, preoperative IOP, or number of antiglaucoma medications (P>0.05)."
Interventions	Intervention 1: apraclonidine 1%, 1 hour before and immediately after 180° ALT Intervention 2: apraclonidine 1%, 1 hour before and immediately after 360° ALT Intervention 3: placebo, 1 hour before and immediately after 180° ALT Length of follow‐up: Planned: 3 hours Actual: 3 hours
Outcomes	Primary outcomes: IOP change, frequency of IOP elevation Secondary outcomes: none reported Adverse events reported: no Intervals at which outcomes assessed: baseline; 1, 2, 3 hours after treatment
Notes	Trial registration: not reported Funding sources: none reported Disclosures of interest: not reported Study period: not reported Reported subgroup analyses: no
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Unclear risk	No information on masking of participants and personnel reported.
Masking of outcome assessment (detection bias)	Low risk	"IOP was measured preoperatively and 1, 2, and 3 hours after treatment by an observer who was blinded to the random assignment of treatment with the drugs."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Study did not address whether outcome data were complete at each time point, but study only lasted 3 hours post‐ALT.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective outcome reporting.
Other bias	Unclear risk	Funding sources not reported.

ALT: argon laser trabeculoplasty; BP: blood pressure; IOP: intraocular pressure; LTP: laser trabeculoplasty; min: minute; N/A: not applicable; Nd:YAG: neodymium‐doped yttrium aluminum garnet; OAG: open‐angle glaucoma; POAG: primary open‐angle glaucoma; RCT: randomized controlled trial; SD: standard deviation; SLT: selective laser trabeculoplasty.